Memantine

Memantine (CAS 19982-08-2), also known as 3,5-dimethyl-1-adamantanamine, is an active pharmaceutical ingredient used in the treatment of moderate-to-severe Alzheimer's disease. It functions as an NMDA receptor antagonist and is the basis for several branded and generic prescription drug products worldwide. As a finished API, it is the primary active ingredient in oral tablet and solution formulations.

Generic drug manufacturers source it as a starting material or advanced intermediate for synthesis of memantine hydrochloride salt, the predominant commercial form used in dosage manufacturing. Contract development and manufacturing organizations (CDMOs) also procure it as a reference standard or process intermediate when developing extended-release formulations for global markets.

Pharmaceutical companies operating in regulated markets source it for inclusion in combination therapies alongside cholinesterase inhibitors. It is supplied as a white crystalline powder for industrial use. Standard grades include USP, EP (Ph. Eur.), and high-purity API-grade material meeting ICH Q7 GMP requirements. These standards ensure the highest level of safety and efficacy for pharmaceutical production.

Bulk quantities are available for commercial manufacturing, with smaller research and reference standard quantities also offered for analytical and development use in laboratory settings.